Ljungman et al., 2010 - Google Patents
Cytomegalovirus in hematopoietic stem cell transplant recipientsLjungman et al., 2010
View PDF- Document ID
- 14280665733317006723
- Author
- Ljungman P
- Hakki M
- Boeckh M
- Publication year
- Publication venue
- Infectious Disease Clinics
External Links
Snippet
Human cytomegalovirus (CMV) is a betaherpesvirus in the same family as human herpesvirus-6 and-7. CMV is a large virus including approximately 200 proteins. CMV has been found in a wide range of cells, including endothelial cells, epithelial cells, blood cells …
- 241000701022 Cytomegalovirus 0 title abstract description 204
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ljungman et al. | Cytomegalovirus in hematopoietic stem cell transplant recipients | |
| Ljungman et al. | Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7) | |
| Kotton | Management of cytomegalovirus infection in solid organ transplantation | |
| Goodrich et al. | Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant | |
| Söderberg et al. | Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection | |
| Boeckh et al. | Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial | |
| Boeckh et al. | How we treat cytomegalovirus in hematopoietic cell transplant recipients | |
| Lilleri et al. | Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants | |
| Bruno et al. | Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival | |
| Winston et al. | Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double-blind trial | |
| Omar et al. | Targeted monitoring of patients at high risk of post‐transplant lymphoproliferative disease by quantitative Epstein–Barr virus polymerase chain reaction | |
| Lilleri et al. | Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation | |
| Trottier et al. | Transfusion‐related Epstein‐Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children | |
| Zhou et al. | First-onset herpesviral infection and lung injury in allogeneic hematopoietic cell transplantation | |
| Nakamura et al. | Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure | |
| Cesaro et al. | The real‐time polymerase chain reaction‐guided modulation of immunosuppression enables the pre‐emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation | |
| Tsoumakas et al. | Epidemiology of viral infections among children undergoing hematopoietic stem cell transplant: Α prospective single‐center study | |
| Pande et al. | Cytomegalovirus infections of the stem cell transplant recipient and hematologic malignancy patient | |
| Tong et al. | Risk factors of CMV infection in patients after umbilical cord blood transplantation: a multicenter study in China | |
| Lazzarotto et al. | Kinetics of cytomegalovirus and Epstein-Barr virus DNA in whole blood and plasma of kidney transplant recipients: Implications on management strategies | |
| Gequelin et al. | Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant | |
| Baldanti et al. | Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation | |
| Bonon et al. | Surveillance of cytomegalovirus infection in haematopoietic stem cell transplantation patients | |
| Yoshikawa | Significance of human herpesviruses to transplant recipients | |
| Green et al. | The role of viral load in the diagnosis, management, and possible prevention of Epstein-Barr virus–associated posttransplant lymphoproliferative disease following solid organ transplantation |